Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Status

Terminated

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02953509

Enrollment

178

Registered

2016-11-02

Start date

2016-11-21

Completion date

2024-03-25

Last updated

2025-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Hodgkin Lymphoma

Brief summary

The primary objectives of this study are: * To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). * To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the efficacy of magrolimab in combination with R-GemOx in autologous stem cell transplant (ASCT) ineligible DLBCL participants.

Interventions

DRUGMagrolimab

Administered intravenously

DRUGRituximab

Administered intravenously on Days 8, 15, and 22 during Cycle 1, followed by 1 dose on Day 1 for Cycles 2 through 6, and Day 1 for every other cycle until Cycle 13

DRUGGemcitabine

Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4

DRUGOxaliplatin

Administered intravenously on Days 11, 23 for Cycle 1 and Days 2 and 15 for Cycles 2 to 4

DRUGAllopurinol

Administered orally during Cycle 1

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * Phase 1b only: B-cell non-Hodgkin's lymphoma (NHL), relapsed or refractory to standard approved therapies * DLBCL Phase 2 cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL) expressing cluster of differentiation (CD) 20, relapsed or refractory to at least 2 prior lines treatment containing anti-CD20 therapy * Indolent lymphoma Phase 2 cohort: Marginal zone or follicular lymphoma, relapsed or refractory to standard approved therapies * DLBCL chemotherapy combination cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL), relapsed or refractory to 1-3 prior lines of treatment * Adequate performance status and hematological, liver and kidney functions * Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy Key

Exclusion criteria

* Active brain metastases * Prior allogeneic hematopoietic cell transplantation * Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents * Second malignancy within the last 3 years * Known active or chronic hepatitis B or C infection or HIV * Pregnancy or active breastfeeding * Prior chimeric antigen receptor (CAR-T) therapy Note: Other protocol defined Inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Antibody Treatment Combination	Up to 28 days	DLTs refer to toxicities experienced during the first 28 days of study treatment that have been judged to be clinically significant and related to study treatment in participant in Phase 1b. A DLT was defined as any Grade 3 or greater AE that was assessed as related to either magrolimab and/or rituximab that occurred during the 4-week DLT observation period. Any treatment-emergent adverse event (TEAE) that was, in the opinion of the Clinical Trial Steering Committee, of potential clinical significance such that further dosing exposed participants to unacceptable risk, was considered a DLT.
Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Chemotherapy Treatment Combination	Up to 28 days	DLTs refer to toxicities experienced during the first 28 days of study treatment that have been judged to be clinically significant and related to study treatment in participant in Phase 1b. DLT was defined as any Grade 3 or greater AE including Grade 4 hematologic toxicity that does not resolve to Grade 2 and delays initiation of cycle 2 by more than 14 days, Grade 4 febrile neutropenia or associated infections, Grade 4 non-hematologic toxicity that does not resolve or decrease to Grade 2 within 1 week, Grade 4 infusion-related reaction (IRR), and recurrent Grade 3 or greater IRR despite optimal pretreatment regimen that was assessed as related to either magrolimab, rituximab, gemcitabine, or oxaliplatin and occurred during the 4-week DLT observation period. Any TEAE that was, in the opinion of the Clinical Trial Steering Committee, of potential clinical significance such that further dosing exposed participants to unacceptable risk, was considered a DLT.
Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	Up to 7.2 years	TEAE's were defined as any AEs with an onset date on or after the study drug start date, no later than 30 days after last dose of any study drug or day before initiation of subsequent line of anti-cancer therapy, whichever is earlier, or the AEs leading to the discontinuation of the study drug. An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product or other protocol imposed intervention, regardless of attribution.
Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	Up to 7.3 years	ORR:CR(complete metabolic response(CMR);complete radiological response(CRR)) or PR(partial metabolic response(PMR);partial radiologic response(PRR)).CMR:PET 5 point-scale(5PS) with 1(no uptake above background,2(uptake≤mediastinum),3(uptake\>mediastinum but≤liver)with/without residual mass;no new lesions;no fluorodeoxyglucose (FDG)-avid disease in bone marrow(BM).CRR:target nodes/nodal masses regressed ≤1.5cm in longest transverse diameter of lesion(LDi);no extra lymphatic disease sites;absent non-measured lesions(NMLs);organ enlargement to normal;no new sites;BM morphology normal.PMR:scores 4(uptake moderately\>liver),5(uptake markedly\>liver,new lesions)with reduced uptake from baseline & residual mass;no new lesion;responding disease at interim/residual disease at end of treatment.PRR:≥50% decrease in sum of perpendicular diameters up to 6 target measurable nodes,extra-nodal sites;absent/normal,regressed,but no increase of NMLs;spleen regressed \>50% length beyond normal; no new sites.

Secondary

Measure	Time frame	Description
Duration of Response (DOR)	Up to 7.3 years	DOR is measured from when first OR is met(CR or PR)until the first date of documented progressive disease\[progressive metabolic disease(PMD);progressive radiologic disease(PRD)\]while on study prior to start of next line anti-cancer therapy.Participants with no progressive disease were censored at last response assessment date.Response assessment post start of anti-cancer therapy was excluded from derivation.OR defined in outcome measure 4.PMD:scores 4(uptake moderately\>liver),5(uptake markedly\>liver,new lesions)with increased uptake from baseline;new FDG-avid foci consistent with lymphoma rather than another etiology;new or recurrent FDG-avid foci in BM.PRD:LDi \>1.5 cm;≥ 50% increase from cross product of LDi & perpendicular diameter(PPD);increase in LDi or shortest axis perpendicular to LDi(SDi) of 0.5 cm for lesions ≤ 2 & 1 cm for lesions \>2 cm;spleen increased by \>50% in length beyond normal;new or recurrent splenomegaly,BM involved;new lesions;progression of pre-existing lesions.
Progression Free Survival (PFS)	Up to 7.3 years	PFS is measured from dose initiation until the first date of objectively documented disease progression (PMD; PRD) or death while on study prior to start of the subsequent line of anti-cancer therapy. Participants who do not have progressive disease & not died were censored at last response assessment date.Response assessments after initiation of the subsequent line of anti-cancer therapy will be excluded from derivation. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake from baseline; new FDG-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in BM. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi & PPD; increase in LDi or SDi of 0.5 cm for lesions ≤ 2 & 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, BM involvement; new lesions; progression of pre-existing lesions. KM estimates of median was reported.
PK Parameter of Magrolimab: AUClast	Phase 1: Pre-dose (12 hours) and 1 and 24 hours post-dose on Day 1 (Cycle 1 Day 1 [C1D1]); pre-dose and 1, 24, and 72 hours post-dose on Day 8 (C1D8) and Day 29 (C2D1); Phase 2 :Pre-dose (12 hours) on Days 1 (C1D1), 8 (C1D8), and 29 (C2D1)	AUClast is defined as the concentration of drug from time zero to the last observable concentration. N = 0 participants for Phase 1b Cohorts 4 and 6, Phase 2 Cohort 3 (DLBCL and iNHL), since PK samples were not collected for Day 1.
Time to Progression (TTP)	Up to 7.3 years	TTP is measured from dose initiation until the first date of objectively documented progressive disease criteria while on study prior to start of next line anti-cancer therapy. Participants with no progressive disease were censored at last response assessment date. Response assessment post start of anti-cancer therapy was excluded from derivation. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new FDG-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; = 50% increase from cross product of LDi and PPD; increase in LDi or SDi of 0.5 cm for lesions =1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. Kaplan-meier (KM) estimates of median was reported.
ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	Up to 7.3 years	Objective response is defined as complete response or partial response determined by LYRIC criteria. ORR:CR\[CMR;CRR\] or PR\[PMR;PRR\].CMR:PET 5 PS with 1(no uptake above background,2(uptake≤mediastinum),3(uptake\>mediastinum but≤liver)with/without residual mass;no new lesions;no FDG-avid disease in BM.CRR:target nodes/nodal masses regressed to ≤1.5cm in LDi;no extralymphatic disease sites;absent NMLs;organ enlargement to normal;no new sites;BM morphology normal.PMR:scores 4(uptake moderately\>liver),5(uptake markedly\>liver,new lesions)with reduced uptake from baseline and residual mass;no new lesion;responding disease at interim/residual disease at end of treatment.PRR: ≥50% decrease in sum of product of perpendicular diameters up to 6 target measurable nodes,extra-nodal sites;absent/normal,regressed,but no increase of NMLs;spleen regressed \>50% in length beyond normal;no new sites.
Overall Survival (OS)	Up to 7.3 years	OS is measured from dose initiation until death.
PK Parameter of Magrolimab: AUCtau	Phase 1: Pre-dose (12 hours) and 1 and 24 hours post-dose on Day 1 (Cycle 1 Day 1 [C1D1]); pre-dose and 1, 24, and 72 hours post-dose on Day 8 (C1D8) and Day 29 (C2D1); Phase 2 :Pre-dose (12 hours) on Days 1 (C1D1), 8 (C1D8), and 29 (C2D1)	AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). N = 0 participants for Phase 1b Cohorts 4 and 6, Phase 2 Cohort 3 (DLBCL and iNHL), since PK samples were not collected for Day 1.
PK Parameter of Magrolimab: Cmax	Phase 1: Pre-dose (12 hours) and 1 and 24 hours post-dose on Day 1 (Cycle 1 Day 1 [C1D1]); pre-dose and 1, 24, and 72 hours post-dose on Day 8 (C1D8) and Day 29 (C2D1); Phase 2 :Pre-dose (12 hours) on Days 1 (C1D1), 8 (C1D8), and 29 (C2D1)	Cmax is defined as the maximum observed concentration of drug. N = 0 participants for Phase 1b Cohorts 4 and 6, Phase 2 Cohort 3 (DLBCL and iNHL), since PK samples were not collected for Day 1.
Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	Up to 4 years	—

Countries

Australia, United Kingdom, United States

Participant flow

Recruitment details

Participants were enrolled at study sites in Australia, the United Kingdom, and the United States.

Pre-assignment details

209 participants were screened.

Participants by arm

Arm	Count
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab Participants with B-cell NHL received 1 mg/kg magrolimab intravenous (IV) infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by weekly maintenance dose of 10 mg/kg magrolimab IV infusion (over 2 hours) on Days 8, 15, and 22 of Cycle 1 and Days 1, 8, 15, and 22 of Cycle 2 and beyond in combination with rituximab 375 mg/m\^2 IV infusion on Days 8, 15, and 22 of Cycle 1, followed by 1 dose on Day 1 of Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Each cycle length was 28 days. The maximum duration of treatment was up to approximately 86.6 months.	3
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab Participants with B-cell NHL received 1 mg/kg magrolimab IV infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by weekly maintenance dose of 20 mg/kg magrolimab IV infusion (over 2 hours) on Days 8, 15, and 22 of Cycle 1 and Days 1, 8, 15, and 22 of Cycle 2 and beyond in combination with rituximab 375 mg/m\^2 IV infusion on Days 8, 15, and 22 of Cycle 1, followed by 1 dose on Day 1 of Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Each cycle length was 28 days. The maximum duration of treatment was up to approximately 83.3 months.	6
Phase 1b Cohort 3: Magrolimab 30 mg/kg + Rituximab Participants with B-cell NHL received 1 mg/kg magrolimab IV infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by weekly maintenance dose of 30 mg/kg magrolimab IV infusion (over 2 hours) on Days 8, 11,15, and 22 of Cycle 1 and Days 1, 8, 15, and 22 of Cycle 2 and beyond in combination with rituximab 375 mg/m\^2 IV infusion on Days 8, 15, and 22 of Cycle 1, followed by 1 dose on Day 1 of Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Each cycle length was 28 days. The maximum duration of treatment was up to approximately 67.9 months.	13
Phase 1b Cohort 4: Magrolimab 45 mg/kg + Rituximab Participants with B-cell NHL received 1 mg/kg magrolimab IV infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by weekly maintenance dose of 45 mg/kg magrolimab IV infusion (over 2 hours) on Days 8, 11, 15, and 22 of Cycle 1 and Days 1, 8, 15, and 22 of Cycle 2 and beyond in combination with rituximab 375 mg/m\^2 IV infusion on Days 8, 15, and 22 of Cycle 1, followed by 1 dose on Day 1 of Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Each cycle length was 28 days. The maximum duration of treatment was up to approximately 29.2 months.	7
Phase 1b Cohort 5: Magrolimab 30 mg/kg + Rituximab + Gemcitabine + Oxaliplatin Autologous stem cell transplant (or transplantation) ineligible DLBCL participants received 1 mg/kg magrolimab IV infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by maintenance dose of 30 mg/kg on Days 8, 11, 15, 22, and 29 of Cycle 1; Days 1, 8, 15, and 22 of Cycle 2 followed by Days 1 and 15 of subsequent cycles. The cycle length was 28 days. Rituximab 375 mg/m\^2 IV infusion was administered on Days 8, 15, 22, and 29 of Cycle 1, followed by 1 dose on Day 1 of Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Gemcitabine 1000 mg/m\^2 and oxaliplatin 100 mg/m\^2 IV infusion were administered as on Days 11 and 23 of Cycle 1 and Days 2 and 15 of Cycles 2 to 4. G-CSF prophylaxis was administered with gemcitabine and oxaliplatin treatment (Cycles 1-4). Allopurinol 300 mg orally daily was administered for the first cycle only. The maximum duration of treatment was up to approximately 23.2 months.	26
Phase 1b Cohort 6: Magrolimab 45 mg/kg + Rituximab + Gemcitabine + Oxaliplatin Autologous stem cell transplant (or transplantation) ineligible DLBCL participants received 1 mg/kg magrolimab IV infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by maintenance dose of 45 mg/kg on Days 8, 11, 15, 22, and 29 of Cycle 1; Days 1, 8, 15, and 22 of Cycle 2 followed by Days 1 and 15 of subsequent cycles. The cycle length was 28 days. Rituximab 375 mg/m\^2 IV infusion was administered on Days 8, 15, 22, and 29 of Cycle 1, followed by 1 dose on Day 1 for Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Gemcitabine 1000 mg/m\^2 and oxaliplatin 100 mg/m\^2 IV infusion were administered as on Days 11 and 23 of Cycle 1 and Days 2 and 15 of Cycles 2 to 4. G-CSF prophylaxis was administered with gemcitabine and oxaliplatin treatment (Cycles 1-4). Allopurinol 300 mg orally daily was administered for the first cycle only. The maximum duration of treatment was up to approximately 10.8 months.	7
Phase 2 Cohort 1: Magrolimab 30 mg/kg + Rituximab Participants with B-cell iNHL (including FL and MZL) and DLBCL received 1 mg/kg magrolimab IV infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by weekly maintenance dose of 30 mg/kg magrolimab IV infusion (over 2 hours) on Days 8, 15, and 22 of Cycle 1, and Days 1 and 15 of subsequent cycles in combination with rituximab 375 mg/m\^2 IV infusion on Days 8, 15, and 22 of Cycle 1, followed by 1 dose on Day 1 of Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Each cycle length was 28 days. The maximum duration of treatment was up to approximately 59.9 months.	43
Phase 2 Cohort 2: Magrolimab 30 mg/kg + Rituximab Participants with B-cell iNHL (including FL and MZL) and DLBCL received 1 mg/kg magrolimab IV infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by weekly maintenance dose of 30 mg/kg magrolimab IV infusion (over 2 hours) on Days 8, 11, 15, and 22 of Cycle 1; Days 1, 8, 15, and 22 of Cycle 2 and Days 1 and 15 of subsequent cycles in combination with rituximab 375 mg/m\^2 IV infusion on Days 8, 15, and 22 of Cycle 1, followed by 1 dose on Day 1 for Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Each cycle length was 28 days. The maximum duration of treatment was up to approximately 15.7 months.	14
Phase 2 Cohort 3: Magrolimab 45 mg/kg + Rituximab Participants with B-cell iNHL (including FL and MZL) and DLBCL received 1 mg/kg magrolimab IV infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by weekly maintenance dose of 45 mg/kg magrolimab IV infusion (over 2 hours) on Days 8, 11, 15, and 22 of Cycle 1; Days 1, 8, 15, and 22 of Cycle 2 and Days 1 and 15 of subsequent cycles in combination with rituximab 375 mg/m\^2 IV infusion on Days 8, 15, and 22 of Cycle 1, followed by 1 dose on Day 1 for Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Each cycle length was 28 days. The maximum duration of treatment was up to approximately 57.4 months.	31
Phase 2 Cohort 4: Magrolimab 30 mg/kg + Rituximab Participants with DLBCL received 1 mg/kg magrolimab IV infusion priming dose (over 3 hours) on Day 1 of Cycle 1, followed by weekly maintenance dose of 30 mg/kg magrolimab IV infusion (over 2 hours) on Days 8, 15, and 22 of Cycle 1; Days 1, 8, 15, and 22 of Cycle 2 and Days 1 and 15 of subsequent cycles in combination with rituximab 375 mg/m\^2 IV infusion on Days 8, 15, and 22 of Cycle 1, followed by 1 dose on Day 1 for Cycles 2 to 6. Thereafter from Cycle 8 and beyond, rituximab was administered on Day 1 of every other cycle (on even cycles). Each Cycle length was 28 days. The maximum duration of treatment was up to approximately 35.3 months.	28
Total~(N=178)	178
Total	356

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006	FG007	FG008	FG009
Overall Study	Consent Withdrawn	1	1	2	1	3	0	4	1	1	4
Overall Study	Death	1	3	3	4	12	3	25	10	21	20
Overall Study	Lost to Follow-up	0	0	0	0	0	0	1	1	1	1
Overall Study	Reason Not Specified	0	2	8	2	11	4	12	2	7	2
Overall Study	Study terminated by sponsor	1	0	0	0	0	0	1	0	1	1

Baseline characteristics

Characteristic	Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Phase 1b Cohort 3: Magrolimab 30 mg/kg + Rituximab	Phase 1b Cohort 4: Magrolimab 45 mg/kg + Rituximab	Phase 1b Cohort 5: Magrolimab 30 mg/kg + Rituximab + Gemcitabine + Oxaliplatin	Phase 1b Cohort 6: Magrolimab 45 mg/kg + Rituximab + Gemcitabine + Oxaliplatin	Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	Phase 2 Cohort 1: Magrolimab 30 mg/kg + Rituximab	Phase 2 Cohort 2: Magrolimab 30 mg/kg + Rituximab	Phase 2 Cohort 3: Magrolimab 45 mg/kg + Rituximab	Phase 2 Cohort 4: Magrolimab 30 mg/kg + Rituximab	Total~(N=178)
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	1 Participants	5 Participants	3 Participants	17 Participants	4 Participants	1 Participants	22 Participants	12 Participants	23 Participants	20 Participants	108 Participants
Age, Categorical Between 18 and 65 years	5 Participants	8 Participants	4 Participants	9 Participants	3 Participants	2 Participants	21 Participants	2 Participants	8 Participants	8 Participants	70 Participants
Age, Continuous	60 years STANDARD_DEVIATION 11.3	61 years STANDARD_DEVIATION 11.4	63 years STANDARD_DEVIATION 15.2	65 years STANDARD_DEVIATION 14.4	70 years STANDARD_DEVIATION 9.5	58 years STANDARD_DEVIATION 12.8	62 years STANDARD_DEVIATION 13.2	71 years STANDARD_DEVIATION 6.7	70 years STANDARD_DEVIATION 11.5	70 years STANDARD_DEVIATION 12.4	66 years STANDARD_DEVIATION 12.7
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants	1 Participants	0 Participants	1 Participants	1 Participants	0 Participants	2 Participants	0 Participants	3 Participants	2 Participants	11 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	5 Participants	12 Participants	7 Participants	24 Participants	4 Participants	3 Participants	41 Participants	14 Participants	28 Participants	24 Participants	162 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	5 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Asian	1 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants	5 Participants
Race (NIH/OMB) Black or African American	0 Participants	1 Participants	0 Participants	2 Participants	0 Participants	0 Participants	2 Participants	0 Participants	1 Participants	1 Participants	7 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	1 Participants	0 Participants	3 Participants	2 Participants	0 Participants	1 Participants	0 Participants	1 Participants	3 Participants	11 Participants
Race (NIH/OMB) White	4 Participants	10 Participants	7 Participants	20 Participants	5 Participants	3 Participants	39 Participants	14 Participants	28 Participants	24 Participants	154 Participants
Region of Enrollment Australia	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	4 Participants	4 Participants
Region of Enrollment United Kingdom	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	4 Participants	1 Participants	3 Participants	2 Participants	12 Participants
Region of Enrollment United States	6 Participants	13 Participants	7 Participants	24 Participants	7 Participants	3 Participants	39 Participants	13 Participants	28 Participants	22 Participants	162 Participants
Sex: Female, Male Female	3 Participants	5 Participants	1 Participants	10 Participants	2 Participants	2 Participants	16 Participants	4 Participants	15 Participants	9 Participants	67 Participants
Sex: Female, Male Male	3 Participants	8 Participants	6 Participants	16 Participants	5 Participants	1 Participants	27 Participants	10 Participants	16 Participants	19 Participants	111 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk
deaths Total, all-cause mortality	1 / 3	4 / 6	5 / 13	4 / 7	12 / 26	3 / 7	26 / 43	10 / 14	22 / 31	21 / 28
other Total, other adverse events	3 / 3	6 / 6	13 / 13	7 / 7	25 / 26	7 / 7	42 / 43	14 / 14	31 / 31	27 / 28
serious Total, serious adverse events	2 / 3	2 / 6	6 / 13	1 / 7	21 / 26	5 / 7	19 / 43	9 / 14	21 / 31	11 / 28

Outcome results

Primary

Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas

ORR:CR(complete metabolic response(CMR);complete radiological response(CRR)) or PR(partial metabolic response(PMR);partial radiologic response(PRR)).CMR:PET 5 point-scale(5PS) with 1(no uptake above background,2(uptake≤mediastinum),3(uptake\>mediastinum but≤liver)with/without residual mass;no new lesions;no fluorodeoxyglucose (FDG)-avid disease in bone marrow(BM).CRR:target nodes/nodal masses regressed ≤1.5cm in longest transverse diameter of lesion(LDi);no extra lymphatic disease sites;absent non-measured lesions(NMLs);organ enlargement to normal;no new sites;BM morphology normal.PMR:scores 4(uptake moderately\>liver),5(uptake markedly\>liver,new lesions)with reduced uptake from baseline & residual mass;no new lesion;responding disease at interim/residual disease at end of treatment.PRR:≥50% decrease in sum of perpendicular diameters up to 6 target measurable nodes,extra-nodal sites;absent/normal,regressed,but no increase of NMLs;spleen regressed \>50% length beyond normal; no new sites.

Time frame: Up to 7.3 years

Population: The Efficacy Analysis Set included all enrolled participants who received at least 1 dose of magrolimab. As prespecified in the statistical analysis plan (SAP), the efficacy results were to be reported for Phase 1b and 2 combined per dose and disease type (for both antibody and chemotherapy combinations).

Arm	Measure	Value (NUMBER)
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	0 percentage of participants
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	0 percentage of participants
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	50.0 percentage of participants
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	20.6 percentage of participants
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	60.0 percentage of participants
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	26.1 percentage of participants
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	33.3 percentage of participants
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	46.2 percentage of participants
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas	71.4 percentage of participants

Primary

Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

TEAE's were defined as any AEs with an onset date on or after the study drug start date, no later than 30 days after last dose of any study drug or day before initiation of subsequent line of anti-cancer therapy, whichever is earlier, or the AEs leading to the discontinuation of the study drug. An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with use of an investigational product or other protocol imposed intervention, regardless of attribution.

Time frame: Up to 7.2 years

Population: The Safety Analysis Set included all participants who received at least 1 dose of any study treatment.

Arm	Measure	Value (NUMBER)
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	100.0 percentage of participants
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	100.0 percentage of participants
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	100.0 percentage of participants
Phase 1b Cohort 4: Magrolimab 45 mg/kg (Loading Dose) + Rituximab	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	100.0 percentage of participants
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	96.2 percentage of participants
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	100.0 percentage of participants
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	97.7 percentage of participants
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	100.0 percentage of participants
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	100.0 percentage of participants
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)	100.0 percentage of participants

Primary

Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Antibody Treatment Combination

DLTs refer to toxicities experienced during the first 28 days of study treatment that have been judged to be clinically significant and related to study treatment in participant in Phase 1b. A DLT was defined as any Grade 3 or greater AE that was assessed as related to either magrolimab and/or rituximab that occurred during the 4-week DLT observation period. Any treatment-emergent adverse event (TEAE) that was, in the opinion of the Clinical Trial Steering Committee, of potential clinical significance such that further dosing exposed participants to unacceptable risk, was considered a DLT.

Time frame: Up to 28 days

Population: The DLT Analysis Set 1 (Antibody Combination) included all enrolled Phase 1b participants in the magrolimab + rituximab cohort who met either of the following criteria:~* The participant experienced a DLT~* The participants completed at least 3 infusions of magrolimab and 2 infusions of rituximab.

Arm	Measure	Value (NUMBER)
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Antibody Treatment Combination	0 percentage of participants
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Antibody Treatment Combination	16.7 percentage of participants
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Antibody Treatment Combination	15.4 percentage of participants
Phase 1b Cohort 4: Magrolimab 45 mg/kg (Loading Dose) + Rituximab	Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Antibody Treatment Combination	16.7 percentage of participants

Primary

Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Chemotherapy Treatment Combination

DLTs refer to toxicities experienced during the first 28 days of study treatment that have been judged to be clinically significant and related to study treatment in participant in Phase 1b. DLT was defined as any Grade 3 or greater AE including Grade 4 hematologic toxicity that does not resolve to Grade 2 and delays initiation of cycle 2 by more than 14 days, Grade 4 febrile neutropenia or associated infections, Grade 4 non-hematologic toxicity that does not resolve or decrease to Grade 2 within 1 week, Grade 4 infusion-related reaction (IRR), and recurrent Grade 3 or greater IRR despite optimal pretreatment regimen that was assessed as related to either magrolimab, rituximab, gemcitabine, or oxaliplatin and occurred during the 4-week DLT observation period. Any TEAE that was, in the opinion of the Clinical Trial Steering Committee, of potential clinical significance such that further dosing exposed participants to unacceptable risk, was considered a DLT.

Time frame: Up to 28 days

Population: The DLT Analysis Set 2 (Chemotherapy Combination)included all enrolled Phase 1b participants in the magrolimab + rituximab, gemcitabine,and oxaliplatin (R-GemOx) cohort who met either of the following criteria in DLT assessment period:~* Participants had DLT at any time after initiation of first infusion of magrolimab, rituximab, and gemcitabine or oxaliplatin~* Participants completed at least 3 infusions of magrolimab, 2 infusions of rituximab, and 1 infusion of gemcitabine and oxaliplatin

Arm	Measure	Value (NUMBER)
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Chemotherapy Treatment Combination	0 percentage of participants
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Chemotherapy Treatment Combination	16.7 percentage of participants

Secondary

Duration of Response (DOR)

DOR is measured from when first OR is met(CR or PR)until the first date of documented progressive disease\[progressive metabolic disease(PMD);progressive radiologic disease(PRD)\]while on study prior to start of next line anti-cancer therapy.Participants with no progressive disease were censored at last response assessment date.Response assessment post start of anti-cancer therapy was excluded from derivation.OR defined in outcome measure 4.PMD:scores 4(uptake moderately\>liver),5(uptake markedly\>liver,new lesions)with increased uptake from baseline;new FDG-avid foci consistent with lymphoma rather than another etiology;new or recurrent FDG-avid foci in BM.PRD:LDi \>1.5 cm;≥ 50% increase from cross product of LDi & perpendicular diameter(PPD);increase in LDi or shortest axis perpendicular to LDi(SDi) of 0.5 cm for lesions ≤ 2 & 1 cm for lesions \>2 cm;spleen increased by \>50% in length beyond normal;new or recurrent splenomegaly,BM involved;new lesions;progression of pre-existing lesions.

Time frame: Up to 7.3 years

Population: Participants in the Efficacy Analysis Set with an objective response (CR + PR) and those who had objective response without a subsequent event of disease progression/death were analyzed. As prespecified in the SAP, the efficacy results were to be reported for Phase 1b and 2 combined per dose and disease type (for both antibody and chemotherapy combinations).

Arm	Measure	Value (MEDIAN)
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Duration of Response (DOR)	NA months
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Duration of Response (DOR)	NA months
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Duration of Response (DOR)	5.5 months
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Duration of Response (DOR)	15.9 months
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Duration of Response (DOR)	21.2 months
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Duration of Response (DOR)	11.3 months
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	Duration of Response (DOR)	NA months
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Duration of Response (DOR)	18.0 months

Secondary

ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas

Objective response is defined as complete response or partial response determined by LYRIC criteria. ORR:CR\[CMR;CRR\] or PR\[PMR;PRR\].CMR:PET 5 PS with 1(no uptake above background,2(uptake≤mediastinum),3(uptake\>mediastinum but≤liver)with/without residual mass;no new lesions;no FDG-avid disease in BM.CRR:target nodes/nodal masses regressed to ≤1.5cm in LDi;no extralymphatic disease sites;absent NMLs;organ enlargement to normal;no new sites;BM morphology normal.PMR:scores 4(uptake moderately\>liver),5(uptake markedly\>liver,new lesions)with reduced uptake from baseline and residual mass;no new lesion;responding disease at interim/residual disease at end of treatment.PRR: ≥50% decrease in sum of product of perpendicular diameters up to 6 target measurable nodes,extra-nodal sites;absent/normal,regressed,but no increase of NMLs;spleen regressed \>50% in length beyond normal;no new sites.

Time frame: Up to 7.3 years

Population: Participants in the Efficacy Analysis Set with available data were analyzed. As prespecified in the SAP, the efficacy results were to be reported for Phase 1b and 2 combined per dose and disease type (for both antibody and chemotherapy combinations).

Arm	Measure	Value (NUMBER)
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	0 percentage of participants
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	0 percentage of participants
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	50.0 percentage of participants
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	22.1 percentage of participants
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	60.0 percentage of participants
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	26.1 percentage of participants
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	33.3 percentage of participants
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	46.2 percentage of participants
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas	71.4 percentage of participants

Secondary

Overall Survival (OS)

OS is measured from dose initiation until death.

Time frame: Up to 7.3 years

Population: Participants in the Efficacy Analysis Set with available were analyzed. As prespecified in the SAP, the efficacy results were to be reported for Phase 1b and 2 combined per dose and disease type (for both antibody and chemotherapy combinations).

Arm	Measure	Value (MEDIAN)
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	Overall Survival (OS)	13.9 months
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Overall Survival (OS)	NA months
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Overall Survival (OS)	32.2 months
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Overall Survival (OS)	8.5 months
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Overall Survival (OS)	NA months
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Overall Survival (OS)	14.0 months
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Overall Survival (OS)	23.7 months
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	Overall Survival (OS)	41.4 months
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Overall Survival (OS)	NA months

Secondary

Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)

Time frame: Up to 4 years

Population: The ADA analysis set included participants with at least one reported ADA result where participants evaluable for ADA incidence were defined as participants with non-missing baseline sample and at least one sample taken after drug administration during the treatment or follow-up observation period that are appropriate for ADA testing (with reportable result). As prespecified in SAP,ADA results were to be reported for Phase 2 (antibody combination) as per maintenance dose level and disease type.

Arm	Measure	Value (NUMBER)
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 1b Cohort 4: Magrolimab 45 mg/kg (Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	6.7 percentage of participants
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	7.7 percentage of participants
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 2 Cohort 3 (DLBCL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 2 Cohort 3 (iNHL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)	0 percentage of participants

Secondary

PK Parameter of Magrolimab: AUClast

AUClast is defined as the concentration of drug from time zero to the last observable concentration. N = 0 participants for Phase 1b Cohorts 4 and 6, Phase 2 Cohort 3 (DLBCL and iNHL), since PK samples were not collected for Day 1.

Time frame: Phase 1: Pre-dose (12 hours) and 1 and 24 hours post-dose on Day 1 (Cycle 1 Day 1 [C1D1]); pre-dose and 1, 24, and 72 hours post-dose on Day 8 (C1D8) and Day 29 (C2D1); Phase 2 :Pre-dose (12 hours) on Days 1 (C1D1), 8 (C1D8), and 29 (C2D1)

Population: The Pharmacokinetics (PK) Analysis Set included all participants who received at least 1 dose of study drug and had measurable concentrations of magrolimab from PK blood samples. Participants in the PK Analysis Set with available data were analyzed. The PK data was reported for Phase 2 (antibody combination) as per maintenance dose level and disease type.

Arm	Measure	Group	Value (MEAN)	Dispersion
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	770 day*micrograms(μg)/milliliters(mL)	Standard Deviation 346
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	1470 day*micrograms(μg)/milliliters(mL)	Standard Deviation 431
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	4260 day*micrograms(μg)/milliliters(mL)	Standard Deviation 1050
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	1810 day*micrograms(μg)/milliliters(mL)	Standard Deviation 426
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 4: Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 4: Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	2300 day*micrograms(μg)/milliliters(mL)	Standard Deviation 280
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	2220 day*micrograms(μg)/milliliters(mL)	Standard Deviation 877
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 3 (DLBCL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 3 (DLBCL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 3 (iNHL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 3 (iNHL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 8 (Cycle 1, Day 8)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 1 (Cycle 1, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUClast	Day 29 (Cycle 2, Day 1)	NA day*micrograms(μg)/milliliters(mL)	—

Secondary

PK Parameter of Magrolimab: AUCtau

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). N = 0 participants for Phase 1b Cohorts 4 and 6, Phase 2 Cohort 3 (DLBCL and iNHL), since PK samples were not collected for Day 1.

Population: Participants in the PK Analysis Set with available data were analyzed. The PK data was reported for Phase 2 (antibody combination) as per maintenance dose level and disease type.

Arm	Measure	Group	Value (MEAN)	Dispersion
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	671 day*μg/mL	—
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	1220 day*μg/mL	Standard Deviation 97
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	4260 day*μg/mL	Standard Deviation 1050
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	1810 day*μg/mL	Standard Deviation 426
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 1b Cohort 4: Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 1b Cohort 4: Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	2300 day*μg/mL	Standard Deviation 280
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	2080 day*μg/mL	Standard Deviation 658
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 3 (DLBCL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 2 Cohort 3 (DLBCL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 3 (iNHL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 2 Cohort 3 (iNHL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 8 (Cycle 1, Day 8)	NA day*μg/mL	—
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 1 (Cycle 1, Day 1)	NA day*μg/mL	—
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: AUCtau	Day 29 (Cycle 2, Day 1)	NA day*μg/mL	—

Secondary

PK Parameter of Magrolimab: Cmax

Cmax is defined as the maximum observed concentration of drug. N = 0 participants for Phase 1b Cohorts 4 and 6, Phase 2 Cohort 3 (DLBCL and iNHL), since PK samples were not collected for Day 1.

Population: Participants in the PK Analysis Set with available data were analyzed. The PK data was reported for Phase 2 (antibody combination) as per maintenance dose level and disease type.

Arm	Measure	Group	Value (MEAN)	Dispersion
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	212 μg/mL	Standard Deviation 54.6
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	0.619 μg/mL	—
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	330 μg/mL	Standard Deviation 123
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	903 μg/mL	Standard Deviation 186
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	1.32 μg/mL	Standard Deviation 1.31
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	485 μg/mL	Standard Deviation 114
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	NA μg/mL	—
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	NA μg/mL	—
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	NA μg/mL	—
Phase 1b Cohort 4: Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	924 μg/mL	Standard Deviation 170
Phase 1b Cohort 4: Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	1862 μg/mL	Standard Deviation 411
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	NA μg/mL	—
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	NA μg/mL	—
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	NA μg/mL	—
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	2096 μg/mL	Standard Deviation 449
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	906 μg/mL	Standard Deviation 160
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	NA μg/mL	—
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	0.477 μg/mL	Standard Deviation 0.178
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	567 μg/mL	Standard Deviation 75.7
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	542 μg/mL	Standard Deviation 188
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	NA μg/mL	—
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	0.496 μg/mL	Standard Deviation 0.353
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	NA μg/mL	—
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	NA μg/mL	—
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	NA μg/mL	—
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	NA μg/mL	—
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	NA μg/mL	—
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	NA μg/mL	—
Phase 2 Cohort 3 (DLBCL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	918 μg/mL	Standard Deviation 251
Phase 2 Cohort 3 (DLBCL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	1858 μg/mL	Standard Deviation 321
Phase 2 Cohort 3 (iNHL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	904 μg/mL	Standard Deviation 414
Phase 2 Cohort 3 (iNHL): Magrolimab 45 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	2186 μg/mL	Standard Deviation 615
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	NA μg/mL	—
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	NA μg/mL	—
Phase 2 Cohort 3 (iNHL): Magrolimab 20 mg/kg (Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	NA μg/mL	—
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 8 (Cycle 1, Day 8)	NA μg/mL	—
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 1 (Cycle 1, Day 1)	NA μg/mL	—
Phase 2 Cohort 4: Magrolimab 30 mg/ kg (No Loading Dose) + Rituximab	PK Parameter of Magrolimab: Cmax	Day 29 (Cycle 2, Day 1)	NA μg/mL	—

Secondary

Progression Free Survival (PFS)

PFS is measured from dose initiation until the first date of objectively documented disease progression (PMD; PRD) or death while on study prior to start of the subsequent line of anti-cancer therapy. Participants who do not have progressive disease & not died were censored at last response assessment date.Response assessments after initiation of the subsequent line of anti-cancer therapy will be excluded from derivation. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake from baseline; new FDG-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in BM. PRD: LDi \>1.5 cm; ≥ 50% increase from cross product of LDi & PPD; increase in LDi or SDi of 0.5 cm for lesions ≤ 2 & 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, BM involvement; new lesions; progression of pre-existing lesions. KM estimates of median was reported.

Time frame: Up to 7.3 years

Population: Participants in the efficacy analysis set with available data were analyzed. As prespecified in the SAP, the efficacy results were to be reported for Phase 1b and 2 combined per dose and disease type (for both antibody and chemotherapy combinations).

Arm	Measure	Value (MEDIAN)
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	Progression Free Survival (PFS)	1.6 months
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Progression Free Survival (PFS)	NA months
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Progression Free Survival (PFS)	5.6 months
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Progression Free Survival (PFS)	1.8 months
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Progression Free Survival (PFS)	7.5 months
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Progression Free Survival (PFS)	2.1 months
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Progression Free Survival (PFS)	5.5 months
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	Progression Free Survival (PFS)	3.9 months
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Progression Free Survival (PFS)	20.3 months

Secondary

Time to Progression (TTP)

TTP is measured from dose initiation until the first date of objectively documented progressive disease criteria while on study prior to start of next line anti-cancer therapy. Participants with no progressive disease were censored at last response assessment date. Response assessment post start of anti-cancer therapy was excluded from derivation. PMD: scores 4 (uptake moderately \> liver), 5 (uptake markedly \> liver, new lesions) with increased uptake compared with baseline; new FDG-avid foci consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow. PRD: LDi \>1.5 cm; = 50% increase from cross product of LDi and PPD; increase in LDi or SDi of 0.5 cm for lesions =1.5 cm and 1 cm for lesions \>2 cm; spleen increased by \>50% in length beyond normal; new or recurrent splenomegaly, bone marrow involvement; new lesions; progression of pre-existing lesions. Kaplan-meier (KM) estimates of median was reported.

Time frame: Up to 7.3 years

Arm	Measure	Value (MEDIAN)
Phase 1b Cohort 1: Magrolimab 10 mg/kg + Rituximab	Time to Progression (TTP)	1.6 months
Phase 1b Cohort 2: Magrolimab 20 mg/kg + Rituximab	Time to Progression (TTP)	NA months
Phase 1b Cohort 3: Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Time to Progression (TTP)	5.6 months
Phase 1b Cohort 5: Magrolimab 30 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Time to Progression (TTP)	1.8 months
Phase 1b Cohort 6: Magrolimab 45 mg/kg (Loading Dose) + Rituximab + Gemcitabine + Oxaliplatin	Time to Progression (TTP)	7.9 months
Phase 2 Cohort 1 (DLBCL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Time to Progression (TTP)	2.0 months
Phase 2 Cohort 1 (iNHL): Magrolimab 30 mg/kg (No Loading Dose) + Rituximab	Time to Progression (TTP)	5.6 months
Phase 2 Cohort 2 (DLBCL): Magrolimab 30 mg/ kg (Loading Dose) + Rituximab	Time to Progression (TTP)	3.9 months
Phase 2 Cohort 2 (iNHL): Magrolimab 30 mg/kg (Loading Dose) + Rituximab	Time to Progression (TTP)	20.3 months

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Objective Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) as Defined by the Investigator According to the Lugano Classification for Lymphomas

Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Antibody Treatment Combination

Phase 1b: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) in Chemotherapy Treatment Combination

Duration of Response (DOR)

ORR (CR + PR) Defined by the Investigator According to the Lymphoma Response to Immunomodulatory Therapy Criteria for Lymphomas

Overall Survival (OS)

Percentage of Participants Who Developed Anti-Magrolimab Antibodies (ADA)

PK Parameter of Magrolimab: AUClast

PK Parameter of Magrolimab: AUCtau

PK Parameter of Magrolimab: Cmax

Progression Free Survival (PFS)

Time to Progression (TTP)